REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

NCT04526106 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

490

Enrollment

INDUSTRY

Sponsor class

Conditions

FGFR2 Amplification
FGFR2 Gene Mutation
FGFR2 Gene Fusion/Rearrangement
FGFR2 Gene Translocation
FGFR2 Gene Activation
Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
Other Solid Tumors, Adult

Interventions

DRUG: RLY-4008

Sponsor

Elevar Therapeutics